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Since a chance for cure was found out in metastatic colorectal cancer (mCRC)
patients undergoing a resection of liver and lung metastases, high tumor
shrinkage by chemotherapy regimens and their combination with targeted
agents have been addressed in potentially resectable mCRC. However, most
mCRC patients cannot reach this opportunity because of tumor burden or
metastatic sites. For these patients a salvage systemic therapy could be offered
to prolong survival. To date, a huge number of clinical trials provided some
evidences for the achievement of this goal. A lot of chemotherapeutic regi-
mens in combination with biological therapies are now available. We tried
to propose a simple way to choose the best options and to plan an optimal
sequence of treatments. This tool could help the oncologists worldwide to
better and easily manage mCRC patients who need salvage systemic therapy.
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Colorectal cancer (CRC) is one of the leading causes of cancer-related death. The
development of metastases is the main event that impacts on survival in CRC
patients. A chance of cure in stage IV CRC patients has arisen since the resection
of liver and lung metastases induced the maintenance of prolonged disease-free
interval in a consistent proportion of patients. Subsequently, the clinical develop-
ment of chemotherapeutic regimens, alone or in combination with targeted agents,
allowed the possibility of resection and cure also in those patients who were not
resectable for liver and lung metastases at diagnosis time. For this reason, till now
an increasing number of clinical trials have been designed and carried out to identify
the best treatment option to achieve a high metastases resection rate and subsequent
prolonged survival [1].
However, a relevant number of metastatic CRC (mCRC) patients show no ways
to receive a resection for distant metastases. In these cases, only salvage therapy can
be offered. Because cure is not possible in these patients, a prolongation of survival,
with preservation or improvement of quality of life, is the main goal of the options
available for these patients. Since a lot of clinical trials with various chemotherapeu-
tic regimens and/or targeted drugs studied different end points, every oncologists
need to choose the best option according to the real aim, which they would achieve
for their patients. For all these reasons, a proper plan of the optimal sequence of
treatments needs to be identified according to many patient- and tumor-related
factors [2].
In the 2012 European Society of Medical Oncology guidelines, Schmoll et al.
included the proposal of a sequence for salvage therapy in mCRC [3]. All the treat-
ment options were included in a complicated algorithm, which would offer to the
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oncologists a way to treat each patient in agreement with his/
her own characteristics. First-line treatment is usually chosen
after the evaluation of some patient-related factors, such as
age, performance status and comorbidity; tumor-related fac-
tors, such as tumor burden and presence of symptoms; and
drug-related factors, such as the availability of drugs and the
predictive markers of efficacy. Anyway the algorithm pro-
posed there is not enough easy to be used. In fact, even though
it includes the most up-to-date treatment options in agree-
ment with evidence-based medicine, it does not let the oncol-
ogists find the optimal sequence easily.
This algorithm starts with a stratification of patients for
first-line treatment in four clinical groups, from 0 to 3,
according to metastatic sites, resectability, potential of the
patient to tolerate systemic therapy. For Group 3 patients,
who do not need primarily a maximal shrinkage of metastases,
fluoropyrimidine alone or in combination with bevacizumab
is proposed as first-line treatment. For the other patients, a
sequence of treatment options is developed starting with
oxaliplatin- or irinotecan-based regimens. The subsequent
regimens used after progression are addressed by the previous
combination with specific targeted drugs, including the anti-
EGFR monoclonal antibodies (moAbs) and bevacizumab.
However, among the treatment options included in this
algorithm, which were studied in various clinical trials, just
few achieved a benefit in overall survival.
In particular, to date no randomized Phase III trials are
available for the comparison between fluorouracil, folinic
acid, irinotecan (FOLFIRI) + bevacizumab versus FOLFIRI,
so that the influence of bevacizumab on response rate, progres-
sion-free survival (PFS) and OS by this combination regimen
has not been known yet. Furthermore, the combination of
oxaliplatin-based regimens with cetuximab showed no addi-
tional benefit in OS and some studies prompted some con-
cerns about safety of this option, as reported in NORDIC
VII and COIN trial [4,5]. The algorithm proposed by
Schmoll et al. allows the development of some sequences com-
posed by four lines of treatment by the delay of targeted agents
delivery. Anyway no evidences of long-term benefit are docu-
mented by the increase of the number of treatment lines.
All these reasons induced us to propose a different way to
identify the optimal sequence for salvage therapy in mCRC
patients (Figure 1). To achieve this goal, we selected only those
Phase III trials that obtained a clear benefit in PFS and/or OS
by the addition of targeted agents to standard doublet
chemotherapeutic regimens (i.e., fluorouracil, folinic acid,
oxaliplatin [FOLFOX] and FOLFIRI) and regorafenib alone,
when chemotherapy may not give further benefit. Since irino-
tecan- and oxaliplatin-based doublets are similar in terms of
survival end points, a classification of the treatment sequences
according to first-line chemotherapeutic backbone drug is not
really useful [6]. To date, the main factor conditioning the
first-line treatment decision-making is KRAS and NRAS
mutation status. Even BRAF mutation seems to have a role
as a predictive factor for the efficacy to anti-EGFR moAbs,
but its prognostic role appears predominant. After the detec-
tion of somatic RAS gene mutations, each oncologist is able
to know if a mCRC patient could have a benefit from the
combination of the anti-EGFR moAbs with standard chemo-
therapy doublets [7]. In fact for RAS wild-type patients the
benefit in OS was observed for both these two combinations:
FOLFIRI + cetuximab, as showed in the CRYSTAL trial [8],
and FOLFOX + panitumumab, as reported in the PRIME
trial after the specific evaluation of both KRAS and NRAS
mCRC
RAS
w/t
1st line
2nd line
3rd line
FOLFIRI +
Cetuximab
FOLFOX +
Bevacizumab
FOLFIRI +
Aflibercept
Regorafenib
FOLFIRI +
Bevacizumab
FOLFOX +
Panitumumab
FOLFOX +
Bevacizumab
RAS
mut
Figure 1. Algorithm for the optimal sequence of salvage treatment regimens in metastatic colorectal cancer.
FOLFIRI: Fluorouracil, folinic acid, irinotecan; FOLFOX: Fluorouracil, folinic acid, oxaliplatin; mCRC: Metastatic colorectal cancer.
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gene mutations [9]. These clear efficacy results are supported
by the lack of consistent crossover in these anti-EGFR-based
trials, since a minority of patients in the control arm received
cetuximab or panitumumab as subsequent treatment.
Conversely, the FOLFOX/XELOX + bevacizumab regimen
showed an improvement of PFS only, not of OS [10]. More-
over, FOLFIRI + bevacizumab has not been compared yet
with FOLFIRI alone in a Phase III trial. For this reason in
KRAS or NRAS-mutated mCRC patients, who cannot receive
anti-EGFR moAbs, FOLFOX + Bevacizumab represents the
best option, instead of FOLFOX or FOLFIRI alone, because
it can delay progression even though it cannot reduce the risk
of death.
The choice of the second-line treatment is mainly influenced
by the scant evidences about a re-challenge with the same che-
motherapeutic regimen. The re-challenge with Bevacizumab
has been showed to give further benefit [11]. For the re-challenge
with Cetuximab some intriguing results have been reported till
now, but strong evidences are not still available [12]. On these
bases, we propose FOLFOX + bevacizumab for those RAS
wild-type patients who received FOLFIRI + cetuximab as
first-line treatment, and FOLFIRI + aflibercept after first-line
treatment with FOLFOX + panitumumab. The first second-
line option is supported by the results from E3200 trial, which
obtained survival benefit through the addition of bevacizumab
to oxaliplatin-based treatment in those patients who did not
receive bevacizumab before [13]. The latter option finds a
support in the VELOUR trial, which reported an OS benefit
when aflibercept was added to FOLFIRI after a previous
treatment with an oxaliplatin-based regimen [14].
In RAS-mutated mCRC patients, who received an oxalipla-
tin-based regimen plus bevacizumab as first-line treatment,
two options are available on the basis of evidence-based findings
from Phase III trials with OS benefit. These chances include
both FOLFIRI + aflibercept according to the VELOUR trial’s
results and FOLFIRI + bevacizumab as highlighted by the
ML18147 trial [11,14]. However, in ML18147 trial the use of
bevacizumab together with FOLFIRI achieved a benefit in
OS. Conversely, in VELOUR trial the aflibercept did not add
benefit in OS in the subgroup of those patients treated
previously with bevacizumab, since the HR for death was
0.862 (95% CI: 0.673 -- 1.104). HR for progression showed
significant improvement through aflibercept in the same sub-
group of patients (HR: 0.661 [95% CI: 0.512 -- 0.852]). For
this reason, in patients with RAS mutation the difference of
results according with the previous treatment with bevacizumab
must be taken into account. Recently an update of VELOUR
trial has been published reporting the results of prespecified
subgroup analysis. The combination of aflibercept with
FOLFIRI in patients withmCRC treated with oxaliplatin indu-
ces benefit accross the specified patient subgroups, including
both the subgroups of patients treated with or without prior
bevacizumab [15].
Anyway the choice between these two second-line options in
RAS-mutated patients could be properly addressed by the time
of progression from first-line treatment with bevacizumab.
In fact, if an early progression arises during the treatment
with an oxaliplatin-based regimen with bevacizumab, a switch
to FOLFIRI + aflibercept is a reasonably more appropriate
option than bevacizumab continuation.
If these possible sequences of first- and second-line
treatments could be carried out, a further effective treatment
opportunity with a targeted drug is now possible. In fact regor-
afenib, a BRAF inhibitor, showed an OS benefit over placebo
in the Phase III CORRECT trial for unselected patients who
previously were treated with irinotecan- and oxaliplatin-based
regimens. Till now no other Phase III trials provided an OS
benefit in these different settings [16].
This new simplified algorithm we propose here does not
eliminate the previous one proposed by Schmoll et al. In
fact, while that one includes all the options available now
for the sequence of salvage chemotherapy, our flow chart
Mono-CT
+
bevacizumab
Worse Normal Perfect
Health status
%
 p
ts
Doublet-CT
+
target drug
Triplet-CT
+
bevacizumab
Figure 2. Perspectives for salvage first-line treatment options according to the general health status.
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provides a tool for the identification of the optimal sequential
strategy of targeted agents and chemotherapy to achieve the
goal of an OS prolongation in mCRC patients. To obtain
this purpose, only those Phase III trials with strong evidence
of survival benefit were taken into account. However, the
plan of the optimal sequence does not exclude that alternative
suboptimal treatment options are searched if particular condi-
tions arise. Moreover, it could be useful to design a new clin-
ical trial for comparison of the different sequences of
treatment strategy.
In the next future, the perspective for the choice of first-line
treatment in the overall population of mCRC patients includes
the evaluation of the general health status (Figure 2). Those
patients with worse health status or advanced age (> 70 years)
could benefit from a combination of fluoropyrimidine-based
monochemotherapy plus bevacizumab. This combination
was showed to be more effective in term of PFS compared
with fluoropyrimidine alone, as reported in MAX and AVEX
trials [17,18].
For patients with normal health status, the first-line
treatment should include an oxaliplatin- or irinotecan-based
doublet in combination with a target agent such as anti-
EGFR or anti-VEGF, taking into account the RAS mutation
status. In this case, the sequence of treatment should follow
the flow chart proposed here.
Finally young patients in perfect health status could have a
further benefit in term of PFS from a triplet chemotherapy,
such as FOLFOXIRI + bevacizumab. Indeed this combina-
tion was showed to reach longer PFS than that achieved
with FOLFIRI + bevacizumab, according to the results of
TRIBE trial [19]. This trial provides interesting results, above
all for the long duration of induction treatment, that is,
12 cycles, and the possibility of continuation of maintenance
treatment with 5-FU and bevacizumab.
A further support to this proposal derives from the recent
published data about FIRE-3 trial, which compares the
combination of chemotherapy and bevacizumab with the
same chemotherapy and cetuximab in KRAS wild-type
mCRC patients [20]. Although these results have not reached
a high level of evidence yet, the use of cetuximab confers a
better OS compared to bevacizumab without difference in
PFS. These findings are controversial and should be better
clarified with further studies, since PFS and OS were not
the primary end points in this trial. Further trials are ongoing
to explore the comparison between anti-EGFR and anti-
VEGF moAbs, such as PEAK and CALGB trial. When the
results from these trials will be definitively published we could
have a further confirmation about the pertinence of our
proposal. The actual decision-making of first-line treatment
in RAS wild-type patients should be only based on CRYSTAL
and PRIME trial with respect to NO16966 trial results.
In conclusion, for mCRC patients who do not have a clear
perspective for a resection of distant metastases, an optimal
sequence of salvage therapy could be planned, including
chemotherapy and targeted agents. An accurate evaluation of
the general health status and age is the fundamental factor
to lead the choice of the most proper combination of chemo-
therapeutic regimens and moAbs for first-line treatment.
mCRC patients with normal health status could receive
doublet chemotherapy in combination with anti-EGFR or
anti-VEGF moAbs according to RAS mutation status. We
previously stated that the choice among drugs addressing
these two targets, EGFR and VEGF, depends on various
clinical and molecular factors [21]. However, the most recent
evidences about the selection of patients by KRAS and
NRAS mutations allowed us to propose a new simplified
algorithm to find the optimal sequence of salvage therapy as
well as we tried to get the Ariadne’s thread in a labyrinth.
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